Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non–small-Cell Lung Cancer In Vivo and In Vitro

Aberrant activation of the Ras–ERK signaling pathway drives many important cancer phenotypes, and several inhibitors targeting such pathways are under investigation and/or approved by the FDA as single- or multi-agent therapy for patients with melanoma and non–small-cell lung cancer (NSCLC). Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chao-Yue, Cao, Di, Ren, Qian-Nan, Zhang, Shan-Shan, Zhou, Ning-Ning, Mai, Shi-Juan, Feng, Bing, Wang, Hui-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275840/
https://www.ncbi.nlm.nih.gov/pubmed/34267658
http://dx.doi.org/10.3389/fphar.2021.684243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275840/
https://www.ncbi.nlm.nih.gov/pubmed/34267658
http://dx.doi.org/10.3389/fphar.2021.684243

Ejemplares similares